Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
about
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular diseaseDiabetes DyslipidemiaAcarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomesCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsCardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patientsEffect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.On the potential of acarbose to reduce cardiovascular disease.Extra-pancreatic effects of incretin-based therapies.A review of gliptins for 2014.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysisComparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin.Factors That Influence Pancreatic Beta Cell Function and Insulin Resistance in Newly Diagnosed Type 2 Diabetes Patients: A Sub-Analysis of the MARCH Trial.Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling.Acarbose versus trans-chalcone: comparing the effect of two glycosidase inhibitors on obese mice.Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI
P2860
Q26740253-8437015A-7362-4C02-B7B7-26DB8B01E73BQ26741067-5C7FD770-E0E1-430D-817F-4F6EDCA705B0Q26750905-23CD3230-D021-4F73-AC21-DC7A8F0B9462Q26778095-8CE40404-BBF7-4E4D-A942-BAEEC58196D0Q26824616-DD4A5F1F-E215-4B98-B163-BBD8FD48A001Q31143283-7CA5C631-417B-49C4-A29F-C10F8FEC43BBQ33887783-F6FFB5C3-2C1D-4F19-8CD9-90E9FD9ADDDEQ34078741-72998DAF-BEF8-472C-9DB9-18CFEFF31C4BQ36448319-F1C3663D-54AF-4D24-B92F-42D01C59543DQ36715125-A8BC03FB-8841-4113-95CF-5CD4A9967190Q37024780-C36B451D-1BB6-4CAE-A012-F1D44A401B94Q37079289-0EFB2CB0-DCCD-4ECD-B379-4107B5743D85Q37586607-18198BF6-43BC-450F-AD6B-82E794460CA1Q37717838-0B1366BE-4BB7-4C8E-A4A7-C42738B8CF1DQ38194069-16CDF8D6-94E5-4382-9AF4-551DB4245A7BQ38266290-031250DE-A38B-4AFD-8B97-996840A2C89BQ38371242-72D3CFCC-8691-4B04-B320-8BCEF03A0272Q38511039-E455E50A-F0B4-43B1-BB3E-87B6C24DBB3EQ38563239-88C71097-CE5F-49F8-8B6B-DEF7CDEFC8CEQ38931845-303016F9-977B-412B-9DE2-B974009E8E66Q40844288-2EC8934C-ECB0-4D23-AC57-FAB37EAE4E3EQ41811814-1E12A3F3-3D88-4107-86CF-B1EA875EC820Q42003332-F14003E9-25D5-4CDB-A851-8BB984DAFA4BQ49193708-240C7895-359B-42D2-9945-245D55750C2DQ51245631-CEECE6AE-4D3B-4FE8-A4A2-04E2D80B9103Q51301791-5963F0D2-F0E7-4704-9655-0C8DB2CFFC82Q51345495-32D438DE-32A3-4578-9D7F-A595D14EE3BDQ52807797-D9A96740-095E-4BEA-A900-39B744CEB7A9Q52932391-2C7F4B63-5B81-4C71-84AA-B6A615B58D82Q58039484-8D13BA8A-1697-41B4-A06D-A764082C6B0E
P2860
Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Effects on lipid profile of di ...... of placebo-controlled trials.
@en
type
label
Effects on lipid profile of di ...... of placebo-controlled trials.
@en
prefLabel
Effects on lipid profile of di ...... of placebo-controlled trials.
@en
P2093
P2860
P1433
P1476
Effects on lipid profile of di ...... of placebo-controlled trials.
@en
P2093
Benedetta Ragghianti
Edoardo Mannucci
Francesca Monami
Giulia Toffanello
Maria Luisa Ambrosio
Matteo Monami
Nadia Bartoli
Niccolò Marchionni
Valentina Vitale
P2860
P2888
P304
P356
10.1007/S12325-012-0045-5
P407
P577
2012-08-24T00:00:00Z
P6179
1014017839